Literature DB >> 23897375

Catatonic schizophrenia: therapeutic challenges and potentially a new role for electroconvulsive therapy?

Deirdre Philbin1, D Mulryan, M O'Grady.   

Abstract

A 36-year-old man with known schizophrenia, presented with increasingly bizarre behaviour. The development of catatonia and subsequent neuroleptic malignant syndrome in itself posed numerous therapeutic challenges. However, following resolution of neuroleptic malignant syndrome, the reintroduction of antipsychotics was not tolerated. This case report proposes a novel use for electroconvulsive therapy as a treatment of mental state, following resolution of neuroleptic malignant syndrome, to facilitate successful reintroduction of antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23897375      PMCID: PMC3736193          DOI: 10.1136/bcr-2013-009153

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

2.  Is risk of neuroleptic malignant syndrome increased in the postpartum period?

Authors:  P J Alexander; R M Thomas; A Das
Journal:  J Clin Psychiatry       Date:  1998-05       Impact factor: 4.384

Review 3.  Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome.

Authors:  R J Gurrera
Journal:  Am J Psychiatry       Date:  1999-02       Impact factor: 18.112

Review 4.  Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases.

Authors:  J N Trollor; P S Sachdev
Journal:  Aust N Z J Psychiatry       Date:  1999-10       Impact factor: 5.744

5.  Aripiprazole and neuroleptic malignant syndrome.

Authors:  Nandini Chakraborty; Timothy Johnston
Journal:  Int Clin Psychopharmacol       Date:  2004-11       Impact factor: 1.659

Review 6.  Malignant syndrome in Parkinson's disease: concept and review of the literature.

Authors:  Yoshikuni Mizuno; Hideki Takubo; Eiiji Mizuta; Sadako Kuno
Journal:  Parkinsonism Relat Disord       Date:  2003-04       Impact factor: 4.891

Review 7.  Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Tracy Swainston Harrison; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Risk factors for neuroleptic malignant syndrome.

Authors:  M J Akpaffiong
Journal:  J Natl Med Assoc       Date:  1992-09       Impact factor: 1.798

9.  Serum iron in catatonia and neuroleptic malignant syndrome.

Authors:  J W Lee
Journal:  Biol Psychiatry       Date:  1998-09-15       Impact factor: 13.382

Review 10.  [Neuroleptic malignant syndrome. Case reports].

Authors:  D Berardi; M Troia; L Veronesi; G Ferrari
Journal:  Minerva Psichiatr       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.